McFarlane Neil F.
- SEC CIK
- 0001681098
In the past year, 3 open-market sale filings worth $1.19M and no purchases.
Current role at each company
- ZVRA Zevra Therapeutics, Inc.President and CEOas of Feb 10, 2026
- COLL Collegium Pharmaceutical, IncDirectoras of May 16, 2024
- ADMS Adamas Pharmaceuticals IncChief Executive Officeras of Nov 24, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $1.19M
- 3 filings
- Net
- −$1.19M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists McFarlane Neil F. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ZVRA Zevra Therapeutics, Inc.
President and CEO4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2026 (view filing) | Feb 9 | 1 day | McFarlane Neil F.President and CEO | SSale | −14.6K | $8.56 | −$125.2K | −3.6%387.2K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | McFarlane Neil F.President and CEO | SSale | −91.0K | $9.38 | −$853.6K | −20.0%364.4K after | 10b5-1 |
| Oct 10, 2025 (view filing) | Oct 10 | Same day | McFarlane Neil F.President and CEO | SSale | −19.5K | $10.82 | −$211.0K | −8.1%222.0K after | 10b5-1 |
| Feb 14, 2025 (view filing) | Feb 13-14 | 1 day | McFarlane Neil F.President and CEO | SSale | −91.8K | $7.92 | −$727.5K | −32.4%191.5K after | 2 lots10b5-1 |